Successfully Navigate Regulations, Unveil Clear Routes to Commercialization & Optimize Test Selection to Accelerate Patient Access to Personalized Medicines for Improved Disease Outcomes in Oncology & Beyond

The 14th World Clinical Biomarkers & Companion Diagnostics Summit returns this September as the leading forum for diagnostic stakeholders. This year, enjoy an extended four-day agenda packed with new content and enhanced networking opportunities, uniting drug developers, diagnostics providers, payers and coalitions to share insights and accelerate biomarker-driven clinical trials.

Whether you're working with small molecules, large biologics, or other modalities, this year’s agenda has been carefully curated to strengthen your early disease biomarker discovery, clinical biomarker strategy, reimbursement clarity, and drug-diagnostics commercialization. Join over 500 fellow senior leaders across Biomarkers, Translational Medicine, Precision Medicine, Companion Diagnostics, Commercialization, Regulation, and more to drive the future of precision medicine and improve patient outcomes.


Screenshot 2024-06-05 150616

A Preview of Your Expert Speakers:

Alexander Lukyanov

Senior Director - Data, A.I., UQ & Genome Sciences

Merck & Co

Ann Fish-Steagall

Senior Vice President - Patient Services & Healthcare Delivery

LUNGevity Foundation

Doris Kim

Vice President - Translational Sciences

Zentalis Pharmaceuticals

Gabriele Allegri

Vice President - Global Commercial Precision Medicine

Johnson & Johnson Services, Inc

Gerard Sanderink

Global Head - Biomarkers & Clinical Bioanalyses


Jennifer Dacpano-Komansky

Global Regulatory Affairs - Precision Medicine Team Lead

Novartis AG

Michael Montalto

Vice President - Precision Medicine

Amgen Inc.

Wen Luo

Chief Executive Officer & Chief Scientific Officer

Denovo Biopharma LLC

Last Year's Highlights:


What's New for 2024:


A Whole New Day

Get involved in 3 full days of data-driven content and interactive discussions this year, with an additional 3.5 hours dedicated to networking, providing actionable insights, industry connections, and cutting-edge knowledge to keep you ahead of the curve.


35 New Biopharma Speakers

Hear from 35 new Key Opinion Leaders pioneering new data, advancing better technologies, and improving regulatory strategies in precision medicine from companies including AstraZeneca, Johnson & Johnson, Zentalis and more.


Brand New Content

Key topic areas include CDx in ADCs, LDT updates, generative AI and unsupervised learning models, transformative fluid biomarkers, non-invasive digital biomarkers and non-oncology biomarkers.

Companies Attending in 2024:

40926 - companies

Confirmed Partners:

Other Events in the Series